By Galux
Our proprietary AI platform is trained to design proteins from first principles, resulting in its modality-agnostic nature. Its unprecedented accuracy has been demonstrated through the de novo design of antibodies, one of the most challenging protein classes to design. At Galux, we develop a pioneering protein therapeutics design platform, GaluxDesign, that uniquely integrates artificial intelligence and physical principles. We bring your imagined proteins to life.
